ArticleFrontiers in genetics2025
Identification of prognostic and cellular senescence gene E2F1 of papillary thyroid carcinoma through bioinformatics analyses and experimental verification.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This work aimed to find a new prognostic cell senescence gene to predict the prognosis of patients with papillary thyroid carcinoma (PTC). Methods: The data of the patients with PTC were collected from the Cancer Genome Atlas (TCGA) database. The gene set of cellular senescence was collected from the website of CellAge. The function of hub genes was analyzed by various bioinformatics methods including expression analysis, survival analysis, and nomogram analyses. Real-time quantitative PCR, cell transfection, colony formation assay, Western blot, wound healing assay, transwell assay, cell counting Kit-8, flow cytometry, and immunohistochemistry staining were performed to verify the function of hub gene. Results: E2F1 was finally screened as the key senescence gene, and its expression was higher in PTC tumors than in normal. KM curve indicated that PTC patients with higher expression of the E2F1 had longer survival times. The GSEA showed that the high expression group of E2F1 was enriched in DNA replication and so on. Cell experiments showed that overexpression of E2F1 significantly increased relative protein expression of senescence related markers, including p21, p53, γ-H2AX, and p16INK4a. Cell experiments also showed that overexpression of E2F1 inhibited the invasion, proliferation, and migration of tumor cells. While knockdown of E2F1 reversed these results. Conclusion: E2F1 was found to be upregulated in PTC, with its high expression significantly correlated to a favorable patient prognosis. E2F1 suppresses malignant tumor phenotypes by modulating cellular senescence. A predictive model integrating E2F1 and clinical features accurately forecasts poor prognosis, indicating E2F1's potential as a therapeutic target for PTC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.